Hermetica Superfood Encyclopedia
The Short Answer
Aerial part extracts of Acanthostyles buniifolius contain a complex sesquiterpene lactone derivative (PubChem CID 14806212) and putative hydroxyanthraquinones that inhibit Trypanosoma cruzi epimastigotes with an IC50 of 2 μg/mL in vitro, a potency matching the most active extracts screened in comparative South American ethnomedicinal studies. This selective antiparasitic activity, observed alongside negligible cytotoxicity against HeLa and Raw264.7 mammalian cell lines, positions the plant as one of the most promising preclinical candidates from Bolivian ethnobotany for Chagas disease intervention, pending in vivo and clinical validation.
CategoryHerb
GroupSouth American
Evidence LevelPreliminary
Primary KeywordAcanthostyles buniifolius benefits
Acanthostyles buniifolius — botanical close-up
Health Benefits
**Antitrypanosomal Activity**
Chloroform extracts of aerial parts inhibit Trypanosoma cruzi epimastigotes at an IC50 of 2 μg/mL and suppress intracellular infection and replication at 15 μg/mL, suggesting multi-stage antiparasitic action relevant to Chagas disease.
**Selective Cytotoxicity Profile**: Extracts demonstrate high selectivity for T
cruzi over mammalian cells (HeLa and Raw264.7 lines), indicating a favorable therapeutic index that distinguishes this plant from more broadly cytotoxic Asteraceae species.
**Anti-inflammatory Potential**
As a member of Asteraceae tribe Eupatorieae, the plant's sesquiterpene lactone constituents are consistent with a class of compounds well-characterized for NF-κB pathway inhibition and prostaglandin suppression, though direct confirmation for this species is pending. **Sesquiterpene Lactone Bioactivity**
The identified compound (CID 14806212), structurally classified among phenylpropanoids, polyketides, coumarins, and their derivatives, represents a scaffold associated with antimicrobial, anti-inflammatory, and cytostatic activities across related Eupatorieae taxa. **Ethnomedicinal Validation of Antiparasitic Use**
Izoceño-Guaraní traditional practitioners use aerial parts specifically for Chagas disease management, providing ethnomedical consensus that aligns with and corroborates the measured in vitro antitrypanosomal data.
**Potential Anthraquinone-Based Mechanisms**
Phylobioactive analysis of related genera suggests hydroxyanthraquinones as a contributing lead chemotype in the tribe, offering a rational basis for future isolation and structure-activity relationship studies targeting T. cruzi enzymes.
**Essential Oil Source**
The aerial parts have been referenced as a source of essential oil with potential aromatic and bioactive applications, consistent with other volatile-oil-rich members of Eupatorieae, though compositional data remain unpublished.
Origin & History
Natural habitat
Acanthostyles buniifolius is a shrub native to South America, with documented collection from the Bolivian Chaco region, particularly among communities such as the Izoceño-Guaraní in the Romero area. It belongs to the family Asteraceae, tribe Eupatorieae, and grows in seasonally dry subtropical habitats characteristic of lowland Bolivia. Cultivation is not formally documented; the plant is harvested from wild populations, with aerial parts (stems, leaves, and flowering tops) collected for ethnomedicinal use.
“Acanthostyles buniifolius occupies a documented place in the ethnomedicinal practice of the Izoceño-Guaraní people of the Bolivian Chaco, where aerial parts of the shrub are employed in the management of Chagas disease (American trypanosomiasis), a vector-borne illness of profound public health significance in this region caused by Trypanosoma cruzi. This traditional use reflects a deep empirical pharmacological knowledge system in which indigenous communities of lowland Bolivia have, over generations, identified plants with antiparasitic relevance in an ecosystem where Triatoma (kissing bug) vectors are endemic. The Asteraceae family to which this plant belongs has broad historical use across South American traditional medicine, with many Eupatorieae tribe members employed as febrifuges, anti-inflammatories, and antiparasitic agents in Andean and lowland communities. Formal ethnobotanical documentation of this specific species remains sparse, with the primary published record emerging from systematic surveys of Bolivian medicinal plants conducted to bridge traditional knowledge and drug discovery for neglected tropical diseases.”Traditional Medicine
Scientific Research
The totality of published evidence for Acanthostyles buniifolius consists of a single peer-reviewed in vitro screening study evaluating aerial part extracts against T. cruzi alongside a panel of South American ethnomedicinal plants collected from Bolivian Izoceño-Guaraní communities; no sample size in the classical clinical sense applies, as the work is entirely cell-culture based. The plant's extract achieved an IC50 of 2 μg/mL against epimastigotes and demonstrated activity in infection/replication assays at 15 μg/mL, outcomes that rank it among the most potent extracts in the screened panel and provide a quantified, reproducible preclinical benchmark. One additional database entry (PubChem CID 14806212) documents a constituent structure from this species, but no pharmacokinetic, pharmacodynamic, animal model, or human study has been published as of the most recent available data. The evidence base is therefore classified as preliminary-preclinical, with the significant caveat that in vitro antiparasitic potency does not reliably predict therapeutic efficacy in vivo, and independent replication, toxicity profiling, and bioavailability studies are entirely absent.
Preparation & Dosage
Traditional preparation
**Traditional Ethnomedicinal Use (Bolivia)**
Aerial parts (stems, leaves, flowering tops) harvested from wild shrubs; specific preparation method (decoction, infusion, poultice) not documented in published literature; used by Izoceño-Guaraní community in the Romero region for Chagas disease management.
**Research Extract Form**
Chloroform (CHRO) extract of dried aerial parts dissolved in DMSO for in vitro assays; stock concentrations prepared to achieve 2–15 μg/mL final assay concentrations; this method is not transferable to human use.
**Effective Dose (In Vitro Reference Only)**
IC50 of 2 μg/mL against T. cruzi epimastigotes; activity in infection assays at 15 μg/mL screening concentration; no human equivalent dose can be extrapolated from these figures.
**Standardization**
No commercial standardized extract exists; no marker compound concentration targets have been established for quality control.
**Essential Oil**
Referenced as an essential oil source, but distillation methods, yield data, and active constituent concentrations in the oil remain unpublished.
**Important Note**
No supplemental dose, therapeutic dose, or safe human dose has been established; self-administration based on current data is not supported by evidence.
Nutritional Profile
No nutritional analysis of Acanthostyles buniifolius has been published; macronutrient, micronutrient, vitamin, and mineral content data are entirely absent from the available scientific literature. The plant is not consumed as a food and has no documented role as a dietary source of carbohydrates, proteins, lipids, or micronutrients. Phytochemically, the confirmed and inferred constituents include a sesquiterpene lactone (PubChem CID 14806212) with a butenolide/coumarin-type lactone moiety, putative hydroxyanthraquinones suggested by phylobioactive analysis of related Eupatorieae taxa, and uncharacterized essential oil volatiles typical of the tribe (which may include monoterpenes and sesquiterpene hydrocarbons). Bioavailability of any constituent is entirely unstudied; the lipophilic nature of sesquiterpene lactones generally suggests moderate oral absorption with significant first-pass metabolism, but no pharmacokinetic data exist for this species.
How It Works
Mechanism of Action
The primary mechanism attributed to Acanthostyles buniifolius extracts is inhibition of Trypanosoma cruzi at multiple life-cycle stages: epimastigotes (replicative insect-stage forms) are suppressed at an IC50 of 2 μg/mL, while intracellular trypomastigote infection and replication in host cells are inhibited at 15 μg/mL screening concentrations, implying interference with parasite replication machinery or membrane integrity rather than a single enzymatic target. The sesquiterpene lactone constituent (CID 14806212), which bears an α,β-unsaturated lactone moiety common to bioactive Eupatorieae metabolites, likely exerts activity through Michael addition to cysteine thiol residues on parasite-specific enzymes such as cruzain (a T. cruzi cysteine protease critical for survival and differentiation), a mechanism well-established for this structural class. Hydroxyanthraquinones inferred from phylobioactive mapping of closely related taxa may additionally contribute through redox cycling, generating reactive oxygen species that overwhelm the parasite's limited antioxidant defenses, including trypanothione reductase. No specific receptor-binding, gene expression, or kinase inhibition data have been directly measured for this species, and molecular target confirmation awaits isolation and mechanistic profiling of pure compounds.
Clinical Evidence
No clinical trials of any phase have been conducted with Acanthostyles buniifolius extracts, standardized preparations, or isolated constituents in human subjects or animal disease models. All quantified outcomes derive from in vitro cell-free and cell-based antiparasitic assays, specifically T. cruzi epimastigote inhibition (IC50 = 2 μg/mL) and intracellular infection suppression at 15 μg/mL, with non-cytotoxicity confirmed in HeLa and Raw264.7 mammalian cell lines. Confidence in therapeutic application is very low due to the complete absence of in vivo pharmacokinetic data, dose-response modeling in organism models, efficacy endpoints, or safety surveillance beyond the limited cytotoxicity screens performed. Prioritization for further research is justified by the strong ethnomedical corroboration from Izoceño-Guaraní practitioners and the quantitatively competitive in vitro potency, but clinical relevance remains entirely unestablished.
Safety & Interactions
The safety profile of Acanthostyles buniifolius is incompletely characterized; the only available data indicate that chloroform extracts at concentrations active against T. cruzi (2–15 μg/mL) do not exhibit cytotoxicity toward HeLa (human cervical carcinoma) or Raw264.7 (murine macrophage) cell lines in vitro, suggesting a favorable selectivity index at those concentrations, but this does not constitute a comprehensive toxicological assessment. No acute, subchronic, or chronic toxicity studies in animal models have been published, no genotoxicity or reproductive toxicity data exist, and no drug interaction profiles have been established, including interactions with standard Chagas disease treatments nifurtimox and benznidazole. Caution is warranted because some Asteraceae species produce sesquiterpene lactones and anthraquinones with hepatotoxic, allergenic, or genotoxic potential at higher doses, and without species-specific safety data, extrapolation from related taxa provides only partial reassurance. Pregnancy, lactation, and pediatric use cannot be assessed due to absent data, and no maximum tolerated dose or no-observed-adverse-effect level (NOAEL) has been determined for any preparation of this plant.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Acanthostyles buniifolius (Meyen ex Walp.) R.M.King & H.Rob.Eupatorium buniifolium Meyen ex Walp.Bolivian Chagas shrubBuniifolia acanthostyles
Frequently Asked Questions
What is Acanthostyles buniifolius used for medicinally?
Acanthostyles buniifolius aerial parts are used by the Izoceño-Guaraní people of Bolivia for the traditional management of Chagas disease, caused by Trypanosoma cruzi. Laboratory studies confirm that chloroform extracts of this shrub inhibit T. cruzi epimastigotes with an IC50 of 2 μg/mL and suppress intracellular infection at 15 μg/mL, supporting the ethnomedicinal rationale, though no human clinical evidence exists.
Is there clinical trial evidence for Acanthostyles buniifolius?
No clinical trials have been conducted with Acanthostyles buniifolius in humans or animal disease models; all evidence is limited to in vitro cell culture assays measuring antiparasitic activity against Trypanosoma cruzi. The plant achieves IC50 values of 2 μg/mL in epimastigote inhibition assays, ranking among the most potent in comparative Bolivian ethnomedicinal screens, but in vitro potency does not predict human clinical efficacy without further pharmacokinetic and in vivo studies.
What bioactive compounds are found in Acanthostyles buniifolius?
The primary characterized compound is a sesquiterpene lactone derivative catalogued as PubChem CID 14806212, structurally classified among phenylpropanoids, polyketides, coumarins, and their derivatives, featuring an α,β-unsaturated lactone moiety associated with antiparasitic and anti-inflammatory activity. Phylobioactive analysis of closely related Eupatorieae taxa also suggests the presence of hydroxyanthraquinones as additional bioactive leads, though their direct isolation from this species has not been published.
Is Acanthostyles buniifolius safe to use?
Safety data for Acanthostyles buniifolius are extremely limited; the only available information shows that active antiparasitic concentrations (2–15 μg/mL) do not cause cytotoxicity in HeLa or Raw264.7 mammalian cell lines in vitro. No animal toxicology, human safety trials, drug interaction studies, or guidance for pregnancy or lactation exist, and the presence of sesquiterpene lactones and possible anthraquinones warrants caution given the hepatotoxic and allergenic potential of structurally related compounds in other Asteraceae species.
What dose of Acanthostyles buniifolius is effective?
No established therapeutic dose for humans or animals has been determined for Acanthostyles buniifolius; the only available dose-response data are from in vitro assays in which chloroform extracts inhibit Trypanosoma cruzi epimastigotes at an IC50 of 2 μg/mL and suppress infection at a 15 μg/mL screening concentration. These concentrations are laboratory reference points dissolved in DMSO and cannot be directly translated into a safe or effective human supplemental dose without bioavailability, pharmacokinetic, and toxicological research.
How does Acanthostyles buniifolius work against Trypanosoma cruzi?
Acanthostyles buniifolius chloroform extracts inhibit T. cruzi epimastigotes at an IC50 of 2 μg/mL and suppress both intracellular infection and replication at 15 μg/mL, indicating multi-stage antiparasitic action. This dual mechanism—targeting both extracellular and intracellular stages of the parasite—makes it potentially relevant for Chagas disease management. The herb appears to disrupt multiple points in the parasite's life cycle rather than relying on a single mode of action.
Does Acanthostyles buniifolius harm human cells while fighting parasites?
Acanthostyles buniifolius demonstrates selective cytotoxicity, meaning it effectively targets Trypanosoma cruzi while showing minimal toxicity to mammalian cell lines tested (HeLa and Raw264.7 cells). This selectivity profile is clinically important because it suggests the herb may suppress parasitic infection at concentrations that spare human tissue. However, selectivity in laboratory conditions does not guarantee safety in whole-organism use, and further human studies are needed.
Which parts of Acanthostyles buniifolius contain the antiparasitic compounds?
The aerial parts (above-ground portions) of Acanthostyles buniifolius contain the bioactive compounds responsible for antitrypanosomal activity, as demonstrated in chloroform extracts used in research. Traditional preparation methods typically utilize these aerial portions rather than roots or other plant material. The specific chemical constituents in these aerial parts are responsible for the observed IC50 values against T. cruzi parasites.
Conditions This May Help
Based on the mechanism and research, Acanthostyles buniifolius (Acanthostyles buniifolius) may support the following health areas. Each link goes to an evidence-ranked guide of the best ingredients for that concern.
Inflammation & Joint Health
Top anti-inflammatories: turmeric, boswellia, omega-3, ginger. Evidence on NF-κB modulation and joint support.
Browse evidence-ranked ingredients →
Immune System Support
Top immune boosters: reishi, chaga, elderberry, vitamin C, zinc. Clinical evidence on immune modulation.
Browse evidence-ranked ingredients →
Cognitive Function & Focus
Top nootropics: lion's mane, bacopa, ginkgo, phosphatidylserine. PubMed-cited evidence on cognitive enhancemen…
Browse evidence-ranked ingredients →
Antioxidant Protection
Top antioxidants: astaxanthin, glutathione, vitamin E, resveratrol. Evidence on oxidative stress protection.
Browse evidence-ranked ingredients →
Weight Management & Metabolism
Weight management supplements: green tea extract, CLA, berberine, fiber. Evidence on metabolism and appetite.
Browse evidence-ranked ingredients →
Or jump to the curated Best Inflammation & Joint Health Stack → top 12 evidence-ranked ingredients.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w acanthostyles-buniifolius-acanthostyles-buniifolius curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
